Industry Specific Issues

Prana Biotechnology in Melbourne has received $5.8 million for clinical research for neurological diseases

April 10th, 2013

Melbourne company Prana Biotechnology has announced it has received a R&D Tax Incentive of A$2.5 million to support its scientific focus upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases. The payment is part of approximately A$5.8 million which is expected to be received for the 2011-12 and 2012-13 financial years. “This Australian Government funded program is commendable because it provides significant amounts of non-dilutive cash to support our ongoing research activities.” commented Geoffrey Kempler, Prana’s Chairman and CEO.

Read More

Swanson Reed appear in The Australian Financial Review

August 14th, 2012

 

Read More

Categories

Archives

    Email this job

    [recaptcha]